What is PHIGENIX?
Phigenix, Inc. operates at the intersection of biotechnology and diagnostic innovation, focusing on the development of targeted therapies and early-detection mechanisms for prostate and breast cancer. The company distinguishes itself through a proprietary pipeline that includes the pioneering use of Human Beta Defensin-1 mRNA to target malignant cells. With a foundational portfolio exceeding 100 patents, Phigenix is strategically positioned to influence the standard of care in personalized medicine, moving beyond traditional diagnostic paradigms toward highly specific, patient-centric therapeutic interventions.
How much funding has PHIGENIX raised?
PHIGENIX has raised a total of $856K across 2 funding rounds:
Private Equity
$842K
Debt
$14K
Private Equity (2014): $842K, investors not publicly disclosed
Debt (2021): $14K led by PPP
Key Investors in PHIGENIX
PPP
Public-Private Partnership
Undisclosed Private Equity
A private equity firm specializing in late-stage capital deployment for companies with significant intellectual property assets in the life sciences sector.
What's next for PHIGENIX?
With the recent infusion of capital, Phigenix is poised to accelerate its clinical development programs and expand its diagnostic footprint. The strategic focus will likely shift toward the commercialization of its cancer vaccine candidates and the broader integration of its diagnostic tests into enterprise-level healthcare systems. As the company matures, the emphasis will remain on validating its mRNA-based therapeutic approaches through rigorous clinical trials, ensuring that its technological advancements translate into measurable improvements in patient outcomes and long-term market viability.
See full PHIGENIX company page
